PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)

Abstract

Objectives: ICLPS, which investigated the achievement of low-density lipoprotein cholesterol (LDL-C) targets in patients receiving lipid-lowering therapy (LLT) in countries outside of Western Europe, demonstrated that dyslipidaemia management was suboptimal. A secondary objective of ICLPS was to investigate healthcare consumption, and these data are presented here. Methods: Patients (n=9049) receiving LLT for ≥3 months who had had their LDL-C value measured on stable LLT in the previous 12 months were included in this cross-sectional observational study conducted between August 2015 and August 2016 in 18 countries in Eastern Europe, Asia, Africa, the Middle-East and Latin America. Data on healthcare resource consumption in the previous 12 months were collected for each patient during a single visit. Data were presented using descriptive statistics. Mixed categorical models were used to identify patient and environmental factors associated with undesired healthcare consumption (≥1 hospitalisation for a cardiovascular reason or ≥1 visit to the emergency room [ER]). Results: Of 20.1% of patients with ≥1 confirmed hospitalisation, 7.9% had hospitalisation for cardiovascular reasons and 35.2% had ≥1 hospitalisation in the intensive care unit (cardiovascular and non-cardiovascular reasons). Overall, 13.8% of patients had ≥1 ER visit. Undesired healthcare consumption was observed in 18.7% of patients (27.8%, 7.7%, 7.7% and 13.2% for very-high, high, moderate and low cardiovascular risk patients, respectively). Factors that increased the rate of undesired healthcare consumption (P<0.05) included being at very-high cardiovascular risk, certain cardiovascular risk factors (hypertension, smoking) and factors that make LDL-C management more difficult (statin intolerance, comorbidities and chronic medication). Conclusions: Undesired healthcare consumption was observed in patients with dyslipidaemia on stable LLT from countries outside of Western Europe, and its rate was increased in patients at very-high cardiovascular risk or who were ‘difficult to treat’. More effective dyslipidaemia management is needed to improve clinical outcomes and reduce healthcare consumption in this patient group.